Literature DB >> 3934317

Escherichia coli K51 and K93 capsular polysaccharides are crossreactive with the group A capsular polysaccharide of Neisseria meningitidis. Immunochemical, biological, and epidemiological studies.

N Guirguis, R Schneerson, A Bax, W Egan, J B Robbins, J Shiloach, I Orskov, F Orskov, A el Kholy.   

Abstract

Eleven Escherichia coli strains, crossreactive with the capsular polysaccharide (CPS) of Neisseria meningitidis group A (GrA), were detected among 645 stool isolates from healthy families in Cairo, Egypt. 10 of these strains were of the O107:K93:H27 or O107:K93:SP serotypes and may be considered descendents of a single bacterium or as a clone. The remaining crossreactive strain was of the O7:K51:H18 serotype. None of the 11 strains produced enterotoxins and none were enteroinvasive. The purified CPS of these E. coli strains, as well as a polysaccharide (PS) from B. pumilis, strain Sh17, precipitated with equine GrA (H49) antiserum. A partial identity between the E. coli K93, K51 and Sh17 PS on the one hand and the GrA CPS on the other was observed by double immunodiffusion when reacted against the H49 antiserum. Four K93 strains and one K51 strain were found among 320 E. coli strains from patients at the Clinical Center, National Institutes of Health, and three K93 strains were found in 105 stool samples from children in Copenhagen. The data from these three surveys suggest that these crossreactive E. coli are common organisms and could serve as a stimulus for "natural" GrA CPS antibodies. Quantitative precipitation analysis showed that K51, K93, and Sh17 PS precipitated 25, 46.8, and 50% of H49 antibodies, respectively. Absorption of H49 antiserum with the GrA CPS removed its precipitating activity with the E. coli K93, K51, and Sh17 PS. Absorption of H49 antiserum with either K51 CPS or Sh17 PS removed the homologous crossreactivity only, whereas K93 CPS absorbed both K93 and K51 reactivities. Antibodies, raised by intravenous injection of formalinized E. coli K93 or K51 cells into rabbits, precipitated with GrA CPS and were bactericidal against GrA meningococci. The crossreaction between the E. coli K93 and the GrA CPS was unexpected since these two CPS are compositionally so dissimilar.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3934317      PMCID: PMC2188001          DOI: 10.1084/jem.162.6.1837

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  44 in total

1.  CHANGING SUSCEPTIBILITY OF MENINGOCOCCI TO ANTIMICROBIAL AGENTS.

Authors:  T C EICKHOFF; M FINLAND
Journal:  N Engl J Med       Date:  1965-02-25       Impact factor: 91.245

2.  Enteric bacteria cross-reactive with Neisseria meningitidis groups A and C and Diplococcus pneumoniae types I and 3.

Authors:  J B Robbins; L Myerowitz; J K Whisnant; M Argaman; R Schneerson; Z T Handzel; E C Gotschlich
Journal:  Infect Immun       Date:  1972-11       Impact factor: 3.441

3.  The immunological responses observed in field studies in Africa with group A meningococcal vaccines.

Authors:  E C Gotschlich; M Rey; J Etienne; W R Sanborn; R Triau; B Cvjetanović
Journal:  Prog Immunobiol Stand       Date:  1971

4.  Antigenic relationship between Escherichia coli and Neisseria meningitidis.

Authors:  O Grados; W H Ewing
Journal:  J Infect Dis       Date:  1970 Jul-Aug       Impact factor: 5.226

5.  Test for Escherichia coli enterotoxin using infant mice: application in a study of diarrhea in children in Honolulu.

Authors:  A G Dean; Y C Ching; R G Williams; L B Harden
Journal:  J Infect Dis       Date:  1972-04       Impact factor: 5.226

6.  Polysaccharides of the genus Bacillus cross-reactive with the capsular polysaccharides of Diplococcus pneumoniae type 3, Haemophilus influenzae type b, and Neisseria meningitidis group A.

Authors:  R L Myerowitz; R E Gordon; J B Robbins
Journal:  Infect Immun       Date:  1973-12       Impact factor: 3.441

Review 7.  Meningococcal disease: still with us.

Authors:  H Peltola
Journal:  Rev Infect Dis       Date:  1983 Jan-Feb

Review 8.  Epidemic meningococcal disease: synthesis of a hypothetical immunoepidemiologic model.

Authors:  J M Griffiss
Journal:  Rev Infect Dis       Date:  1982 Jan-Feb

Review 9.  Some observations on the pneumococcus and on the current status of pneumococcal disease and its prevention.

Authors:  R Austrian
Journal:  Rev Infect Dis       Date:  1981 Mar-Apr

10.  Protection against group B meningococcal disease. III. Immunogenicity of serotype 2 vaccines and specificity of protection in a guinea pig model.

Authors:  C E Frasch; J D Robbins
Journal:  J Exp Med       Date:  1978-03-01       Impact factor: 14.307

View more
  18 in total

1.  Meningococcal group C conjugate vaccines.

Authors:  J Maclennan
Journal:  Arch Dis Child       Date:  2001-05       Impact factor: 3.791

2.  Direct and rapid identification and genogrouping of meningococci and porA amplification by LightCycler PCR.

Authors:  Paula Mölling; Susanne Jacobsson; Anders Bäckman; Per Olcén
Journal:  J Clin Microbiol       Date:  2002-12       Impact factor: 5.948

Review 3.  Prospects for vaccine prevention of meningococcal infection.

Authors:  Lee H Harrison
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

4.  Seroprevalence of antibodies against serogroup C meningococci in England in the postvaccination era.

Authors:  Caroline L Trotter; Ray Borrow; Jamie Findlow; Ann Holland; Sarah Frankland; Nick J Andrews; Elizabeth Miller
Journal:  Clin Vaccine Immunol       Date:  2008-09-30

5.  Immunogenicity of meningococcal ACYW135 polysaccharide vaccine in Saudi children 5 to 9 years of age.

Authors:  M Khalil; Y Al-Mazrou; P Balmer; J Bramwell; N Andrews; R Borrow
Journal:  Clin Diagn Lab Immunol       Date:  2005-10

6.  Streptococcus pneumoniae serotype 1 burden in the African meningitis belt: exploration of functionality in specific antibodies.

Authors:  S Blumental; J C Moïsi; L Roalfe; M Zancolli; M Johnson; P Burbidge; R Borrow; S Yaro; J E Mueller; B D Gessner; D Goldblatt
Journal:  Clin Vaccine Immunol       Date:  2015-02-04

7.  Preparation and characterization of group A meningococcal capsular polysaccharide conjugates and evaluation of their immunogenicity in mice.

Authors:  Zhigang Jin; Chiayung Chu; John B Robbins; Rachel Schneerson
Journal:  Infect Immun       Date:  2003-09       Impact factor: 3.441

8.  Relation between structure and immunologic properties of the Vi capsular polysaccharide.

Authors:  S C Szu; X R Li; A L Stone; J B Robbins
Journal:  Infect Immun       Date:  1991-12       Impact factor: 3.441

9.  Development and use of a serum bactericidal assay using pooled human complement to assess responses to a meningococcal group A conjugate vaccine in African toddlers.

Authors:  Margaret C Bash; Freyja Lynn; Brian Mocca; Ray Borrow; Helen Findlow; Musa Hassan-King; Marie-Pierre Preziosi; Olubukola Idoko; Samba Sow; Prasad Kulkarni; F Marc Laforce
Journal:  Clin Vaccine Immunol       Date:  2014-03-26

10.  Persistence of antibodies in laboratory staff immunized with quadrivalent meningococcal polysaccharide vaccine.

Authors:  Johannes Elias; Jamie Findlow; Ray Borrow; Angelika Tremmel; Matthias Frosch; Ulrich Vogel
Journal:  J Occup Med Toxicol       Date:  2013-03-04       Impact factor: 2.646

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.